Canada Pension Plan Investment Board Invests $28.45 Million in Illumina, Inc. $ILMN

Canada Pension Plan Investment Board purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, Holdings Channel reports. The fund purchased 161,810 shares of the life sciences company’s stock, valued at approximately $28,451,000.

Other large investors have also recently modified their holdings of the company. Legal & General Group Plc bought a new position in Illumina in the second quarter worth approximately $206,299,000. The Manufacturers Life Insurance Company purchased a new position in Illumina during the 2nd quarter worth $20,419,000. Fiduciary Financial Advisors bought a new stake in Illumina during the 2nd quarter valued at $26,000. L2 Asset Management LLC bought a new stake in Illumina during the 2nd quarter valued at $2,576,000. Finally, Patient Capital Management LLC purchased a new stake in shares of Illumina in the 2nd quarter worth $60,717,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. Leerink Partners lifted their price objective on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Royal Bank Of Canada increased their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Barclays raised their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and an average price target of $188.40.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 2,034,688 shares of company stock worth $417,970,281 in the last quarter. 2.90% of the stock is owned by insiders.

Illumina Stock Down 5.3%

Shares of NASDAQ ILMN opened at $215.59 on Friday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The stock’s fifty day simple moving average is $194.05 and its two-hundred day simple moving average is $155.60. The stock has a market capitalization of $32.55 billion, a PE ratio of 40.22, a price-to-earnings-growth ratio of 3.20 and a beta of 1.45. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.